A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

Inclusion Criteria:

Pathologically confirmed prostatic adenocarcinoma.
History of metastatic disease.
Chemically or surgically castrate.
Subject has received at least 2 lines of systemic therapy approved for mCRPC, with disease progression on the most recent systemic therapy as defined in Prostate Cancer Working Group 3 (PCWG3) recommendations.
Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV)-infected subjects that have been cured or who are on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
An Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.
Subject must have adequate heart, liver, bone marrow and kidney function (e.g. estimated glomerular filtration rate [eGFR] ≥ 50 mL/min, aspartate aminotransferase [AST]/alanine aminotransferase [ALT] ≤ 3 x upper limit of normal [ULN], hemoglobin [Hgb] ≥ 9 g/dL (without blood transfusion within 7 days from screening assessment), platelets ≥ 100,000 / mm^3 (without platelet transfusion within 7 days from screening assessment), absolute neutrophil count [ANC] ≥ 1500 / mm^3).

Exclusion Criteria:

Subject has been diagnosed with or treated for another malignancy within the past 2 years whose natural history or treatment may interfere with the safety or efficacy assessment of the investigational regimen.
History of neuroendocrine differentiation in the subject's disease.
Subject has a history of central nervous system (CNS) involvement by their mCRPC. Metastases stemming from bone are allowed.
Subject has clinically significant CNS pathology.
Subject requires chronic immunosuppressive therapy.
Subject has a history of major cardiac abnormalities.